open access
Factors determining therapeutic activity of L-asparaginase
Affiliations- Klinika Pediatrii, Onkologii, Hematologii i Diabetologii Uniwersytetu Medycznego w Łodzi, Uniwersytecki Szpital Kliniczny nr 4 im. M. Konopnickiej, Łódź, Polska
open access
Abstract
L-asparaginase (L-asp) is the basis of contemporary protocols used in the treatment of pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomas. The key factor during L-asparaginase treatment is achieving sufficient serum activity of the drug during particular time period. There are several specified factors influencing L-asp activity. One is the preparation of the enzyme and their different pharmacokinetics. The other is L-asparaginase inactivation due to immunological response. The next factor, indirectly affecting L-asp activity, is the expression of asparagine synthetase, which is an enzyme of the opposite function to L-asparaginase.
The least known process is the enzymatic degradation of L-asparaginase by lisosomal cathepsin B and asparaginyl endopeptidase.
Abstract
L-asparaginase (L-asp) is the basis of contemporary protocols used in the treatment of pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomas. The key factor during L-asparaginase treatment is achieving sufficient serum activity of the drug during particular time period. There are several specified factors influencing L-asp activity. One is the preparation of the enzyme and their different pharmacokinetics. The other is L-asparaginase inactivation due to immunological response. The next factor, indirectly affecting L-asp activity, is the expression of asparagine synthetase, which is an enzyme of the opposite function to L-asparaginase.
The least known process is the enzymatic degradation of L-asparaginase by lisosomal cathepsin B and asparaginyl endopeptidase.
Keywords
Antineoplastic agents; Leukemia; Treatment outcome; Pediatrics
About this articleTitle
Factors determining therapeutic activity of L-asparaginase
Journal
Issue
Pages
35-40
Published online
2014-01-01
Page views
96
Article views/downloads
423
DOI
10.1016/j.achaem.2013.09.001
Bibliographic record
Acta Haematol Pol 2014;45(1):35-40.
Keywords
Antineoplastic agents
Leukemia
Treatment outcome
Pediatrics
Authors
Justyna Walenciak
Beata Zalewska-Szewczyk